SCHEMBL3774276

SCHEMBL3774276

O=C(CN1CCN(c2ccc(-c3ccc(Cl)c(F)c3)nn2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 8/20 0.42
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
HRH3 Q9Y5N1 3/20 0.39
GRM5 P41594 2/20 0.38
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK3 Q15120 1/20 0.37
PDK4 Q16654 1/20 0.37
CCR3 P51677 1/20 0.37
TSHR P16473 1/20 0.37
GFER P55789 1/20 0.36
SCD O00767 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761224 0.93 PANK3 (0.42) PANK3MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3767885 0.92 HRH3 (0.43) PANK3MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3771420 0.92 HRH3 (0.41) PANK3CYP11B1CYP11B2HRH3GRM5
SCHEMBL3776104 0.90 GRM5 (0.49) PANK3CYP11B1CYP11B2HRH3GRM5
SCHEMBL3780493 0.90 GRM5 (0.41) PANK3MAPTNPSR1CYP11B1CYP11B2
SCHEMBL3774746 0.87 LMNA (0.46) ALDH1A1MAPTHRH3TSHR
SCHEMBL3767633 0.87 HRH3 (0.46) KMT2ASMN1; SMN2ALDH1A1MAPTCYP11B1
SCHEMBL3767918 0.87 HRH3 (0.47) PANK3MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3779465 0.87 MEN1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3763255 0.86 HRH3 (0.43) KMT2AMAPTNPSR1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 PANK3 548/4885MEN1 3270/4885KMT2A 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.